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1. Introduction
Stable  gastric  pentadecapeptide  BPC 157  (GEPPPGKPADDAGLV,  M.  W.  1419,  a  partial
sequence of human gastric juice protein BPC, in all studies used peptide with 99% (HPLC)
purity, freely soluble in water at pH 7. 0 and in saline), was always given alone, without any
carrier, µg-ng dose ranges and ways of application, intraperitoneal, intragastrical, in drinking
water or topically, at the site of injury. Besides, tested in therapy of inflammatory bowel disease
(IBD) (PL 14736) in clinical phase II. (Ruenzi et al., 2005), and now in multiple sclerosis.
As prime importance, BPC 157 was found to be stable at least 24 hours in human gastric juice
and consequently, because of its anti-ulcerogenic potential in different, but relevant ulcer
models, suggested to be novel mediator of Robert’s cytoprotection and adaptive cytoprotection
(for review see, i. e., (Sikiric et al., 2010, 2011, 2012)), and thereby, exhibited a particular wound
healing effect, and cell protecting ability. At the general level this may likely explain its strong
effectiveness and LD1 not achieved.
Thereby, such kind of pathophysiologic importance along with unlimited applications of BPC
157 regimens contrasts with the evidence for standard peptides providing that regardless
commonly acknowledged pathophysiologic importance at least in many occasions they need
a carrier (one or more) to become effective and furthermore, that their application prefers to
be local, at the site of injury, given into the injury defect (for review see, i. e., (Urist, 1996)).
Therefore, pentadecapeptide BPC 157 certainly avoids a common scenario with standard
peptides where their limited application in pharmacology could hardly acknowledge their
suggested prime physiological importance (Sikiric et al., 2010, 2011, 2012, 2013, 2014; Seiwerth
et al., 2014)
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2. Methods
With BPC 157 given alone, without a carrier, BPC 157 application strategy (for review see, i.
e., (Sikiric et al., 2010, 2011, 2012, 2013, 2014; Seiwerth et al., 2014)) considerably overrides the
standard peptides and their use with different carriers (i. e., peptide+carrier(s) complex) to
establish the therapeutic effect (thereby erroneously) ascribed to the given peptide. Therefore,
the activity – methodology dilemma whereby it is difficult to identify the real active part in
peptide+carrier complex (peptide, carrier, peptide+carrier complex or neither of them) or
specify their particular contribution is not applicable to BPC 157 (for review see, i. e., Urist,
1996). Finally, in BPC 157 – standard peptides relation, apart from the evidence that this anti-
ulcer peptide may be effective in both upper and lower GI tract injuries (for review see, i. e.,
(Sikiric et al., 2010, 2011, 2012)), and initial successful use in clinic (Ruenzi et al., 2005), involving
also a particular sphincter function control (Sikiric et al., 2010, 2011, 2012), the key difference
appears in the healing outside the GI tract. This may be also because since this evidence was
based on clear demonstration that it also may interact with the general systems, i. e., the NO-
system, providing endothelium protection and angiogenic effect (Seiwerth et al. 2014; Sikiric
et al., 2014). And even more, important to counteract severe complications of advanced and
poorly controlled IBD, this occurs even in severely impaired conditions. Notably, the final
background was that it stimulated expression of early growth response 1 gene (egr-1) respon‐
sible for cytokine and growth factor generation and early extracellular matrix (collagen)
formation (but also its repressor nerve growth factor 1-A binding protein-2 (naB2)) (Tkalcevic
et al., 2007).
To this point, it should be noted that BPC 157 markedly improves the healing of both traumatic
nerve (Gjurasin et al., 2010) and traumatic brain injury (Tudor et al., 2010), and therefore,
exhibits particular neuroprotective ability. Likewise, it ameliorates encephalopathies that
occur in severely intoxicated animals (Ilic et al., 2010, 2011, 2011).
In addition, BPC 157 has in general a very safe profile. As an illustration, single dose toxicity
studies in mice treated by oral and i. v. routes revealed a LD50 of PL 14736 higher than 2000
mg/kg. No mice died during both studies and transient sedation was the only finding in the
dose of 2000 mg/kg. In the 4-week repeated i. v. dosing toxicity studies in rats and dogs no
morphological findings related to PL 14736 administration were found at any of doses studied.
Macroscopical and histological examination of the organs and tissues sampled following 14-
day intracolonic administration in rats and dogs did not reveal changes that could be attributed
to treatment with PL 14736 (doses up to 25 mg/kg). The only finding, lesions at the area of
colon application site in rats, also seen in the control animals, was primarily caused by
mechanical trauma of the catheter used. No effect of PL 14736 on female fertility and early
embryonal development was noted. No effect of PL 14736 in sensitization study and in acute
eye irritation/corrosion study was noted. PL 14736 does not cause chromosomal aberrations
in cultures of human lymphocytes, nor it is mutagenic in the AMES test (doses up to 5 mg/
plate were tested). Repeated i. v. administration of 10-30 µg/kg/day to mice did not induce the
induction of microsomal liver enzymes in vitro. Safety pharmacology of PL 14736 has been
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studied in anaesthetised dogs following intraduodenal administration of 10 and 100 µg/kg,
with no significant effects on the cardiovascular and respiratory systems.
Based largely upon the use of neurotoxin capsaicin, peptidergic neurons have been postulated
to be involved in a physiological protective system (Holzer, 1991,1991). Protection of the gastric
mucosa from various forms of injury occurs with different peptides given centrally (Heiling
et al., 1987; Hernandez, 1986; Hernandez et al., 1987) and/or peripherally (Evangelista et al.,
1991; Takeuchi et al., 1979).
The integrity of capsaicin somatosensory neurons and their protection were suggested to be
related to BPC 157 activity in nociception (Sikiric et al., 1993). Capsaicin-sensitive afferent
neurons, regulators of vascular functions in many somatic and visceral tissues (Holzer, 1991,
1991), are involved in local blood flow regulation in gastrointestinal tract (Holzer, 1991, 1991;
Szabo et al., 1985). The population of capsaicin-sensitive neurons is heterogenous and com‐
prises most but not all primary afferent neurons with small cells body and unmyelinated (C
fiber) axons and some afferent neurons with thinly myelinated (A-δ) axons (Holzer, 1991,
1991). Low doses of capsaicin (micrograms per kilogram range) appear to be protective to the
mucosa (Holzer, 1991, 1991) since they induce a transient excitation. In contrast, systemic
administration of high doses of capsaicin (miligrams per kilogram range) is deleterious,
causing long-lasting damage to these neurons (Holzer, 1991). This effect is age-dependent,
being even more pronounced in the adult rat when capsaicin is given to newborn animals
(Jancsó et al., 1977).
Therefore, the possibility that BPC 157 causes mucosal protection trough capsaicin-sensitive
nerves was challenged. The effect of BPC 157 on gastroprotection, in rats treated with capsaicin,
was investigated. Because of the mentioned different susceptibility to capsaicin of the adult
and newborn animals (Holzer, 1991; Jancsó et al., 1977), and to achieve better insight into a
possible mechanism of BPC 157 activity against the background of near maximal neuronal
damage, it was necessary to use two different methods to deactivate sensory neurons by
capsaicin pretreatment (Holzer, 1991; Jancsó et al., 1977), one in adult rats, the other in newborn
rats. Likewise, since the importance of prostaglandins in organoprotection is well known
(Robert, 1979; Schmidt et al., 1991), these effects were investigated with and without prosta‐
glandin synthesis inhibition by indomethacin (Sikiric et al., 1988).
Stable gastric pentadecapeptide BPC 157 is an originally anti-ulcer peptide implemented in
inflammatory bowel disease trials, and now multiple sclerosis, LD1 could be not achieved
recently largely reviewed (Sikiric et al., 2010, 2011, 2012, 2013, 2014; Seiwerth et al., 2014).
The integrity of capsaicin somatosensory neurons and their protection were suggested to be
related to the activity of BPC 157 (Sikiric et al., 1996).
Therefore, from this viewpoint, the focus was on the gastroprotective effect of the pentadeca‐
peptide BPC 157, on gastric lesions produced in rats by 96% ethanol, restraint stress, and
indomethacin (Sikiric et al., 1996). The possible involvement of sensory neurons in the salutary
actions of BPC 157 (10 micrograms/kg, 10 ng/kg intraperitoneally) was studied with capsaicin,
which has differential effects on sensory neurons: a high dose in adult (125 mg/kg subcutane‐
ously, 3 months old) or administration (50 mg/kg subcutaneously) to neonatal animals (age of




the 7 days) destroys sensory fibers, whereas a low dose (500 micrograms/kg intraperitoneally)
activates neurotransmitter release and protective effects on the mucosa (Table 1-4). In the
absence of capsaicin, BPC 157 protected gastric mucosa against ethanol, restraint, and indo‐
methacin application. In the presence of neurotoxic doses of capsaicin, the negative influence
of capsaicin on restraint, ethanol, or indomethacin lesions consistently affected salutary
activity of BPC 157. However, BPC 157 protection was still evident in the capsaicin-treated rats
(either treated as adults or as newborns) in all of these assays. Interestingly, after neonatal
capsaicin treatment, a complete abolition of BPC 157 gastroprotection was noted if BPC 157
was applied as a single nanogram-regimen, but the mucosal protection was fully reversed
when the same dose was used daily. In line with the excitatory dose of capsaicin the beneficial
effectiveness of BPC 157 appears to be increased as well (Table 4). Taken together, these data
provide evidence for complex synergistic interaction between the beneficial effectiveness of
BPC 157 and peptidergic sensory afferent neuron activity (Sikiric et al., 1996). In broader sense,
this should be a basis for further suitable generalization that was evidenced with transected
peripheral nerve, traumatic brain injury, and brain lesions and subsequent disturbances
(somatosensory disorientation, seizures, catalepsy/stereotypies) induced by various agents
applications (BobanBlagaic et al., 2005; Gjurasin et al., 2010;Ilic et al., 2010, 2011, 2011; Jelovac
et al., 1998, 1999; Klicek et al., 2013; Sikiric et al., 1999;Tohyama et al., 2004; Tudor et al., 2010).
Particularly, the evidence that it both protected somatosensory neurons against capsaicin
neurotoxicity and restored their function (Sikiric et al., 1996) suggests BPC 157 as an agent with
neuroprotective properties (Sikiric et al., 1996). One extension could be the healing of rat
transected sciatic nerve and improvement made by stable gastric pentadecapeptide BPC 157
(10 microg, 10ng/kg) applied shortly after injury intraperitoneally/ intragastrically /locally, at
the site of anastomosis, or after non-anastomozed nerve tubing (7 mm nerve segment resected)
(It is known that the spontaneous regenerative capabilities of the nerve stumps, as well as
Schwann cells abilities to provide a permissive environment for axonal elongation, are
insufficient when there is a 7 mm gap between nerve ends in rat, which also presents an obstacle
for the standard therapy (Gold, 2000)) directly into the tube) (Gjurasin et al., 2010). Improve‐
ment was shown clinically (autotomy), microscopically/morphometrically and functionally
(EMG, one or two months post-injury, walking recovery (sciatic functional index (SFI)) at
weekly intervals). BPC 157-rats exhibited faster axonal regeneration: histomorphometrically
(improved presentation of neural fascicles, homogeneous regeneration pattern, increased
density and size of regenerative fibers, existence of epineural and perineural regeneration,
uniform target orientation of regenerative fibers, and higher proportion of neural vs. connec‐
tive tissue, all fascicles in each nerve showed increased diameter of myelinated fibers, thickness
of myelin sheet, number of myelinated fibers per area and myelinated fibers as a percentage
of the nerve transected area and the increased blood vessels presentation), electrophysiologi‐
cally (increased motor action potentials), functionally (improved SFI), the autotomy absent.
Thus, BPC 157 markedly improved rat sciatic nerve healing with particular point that severe
autotomy – regularly present after transected sciatic nerve – was practically completely
avoided in BPC 157-treated rats (Gjurasin et al., 2010).
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The further extension could be the effect of BPC 157 after an induced traumatic brain injury
(TBI) in mice by a falling weight. BPC 157 regimens (10 micrograms/kg, 10 ng/kg intraperito‐
neally) demonstrated a marked attenuation of damage with an improved early outcome and
a minimal postponed mortality throughout a 24h post-injury period. Ultimately, the traumatic
lesions (subarachnoidal and intraventricularhaemorrhage, brain laceration, haemorrhagic
laceration) were less intense and consecutive brain edema had considerably improved. Given
prophylactically (30 min before TBI) the improved conscious/unconscious/death ratio in TBI-
mice was after force impulses of 0. 068 Ns, 0. 093 Ns, 0. 113 Ns, 0. 130 Ns, 0. 145 Ns, and 0. 159
Ns. Counteraction (with a reduction of unconsciousness, lower mortality) with both microg-
and ng-regimens included the force impulses of 0. 068-0. 145 Ns. A higher regimen presented
effectiveness also against the maximal force impulse (0. 159 Ns). Furthermore, BPC 157
application immediately prior to injury was beneficial in mice subjected to force impulses of
0. 093 Ns-TBI. For a more severe force impulse (0. 130 Ns, 0. 145 Ns, or 0159 Ns), the time-
relation to improve the conscious/unconscious/death ratio was: 5 min (0. 130 Ns-TBI), 20 min
(0. 145 Ns-TBI) or 30 min (0. 159 Ns-TBI) (Tudor et al., 2010)
3. Results
In conclusion, these results should be viewed with numerous compounds and neuroprotective
strategies more extensively discussed, evaluated and reviewed elsewhere (Maas et al., 2005;
Marklund et al., 2006). However, brain trauma results in brain damage and dysfunction from
both primary injury (due to biomechanical effects) and subsequent secondary damage due to
activation of pathophysiologic cascades (Muir, 2006), and this study with BPC 157 (Tudor et
al., 2010) evidenced the preserved consciousness and reduced mortality immediately after
trauma in pentadecapeptide BPC 157-mice and subsequently, markedly reduced mortality,
lowered brain edema, lowered the number and size of haemorrhagic traumatic lacerations,
and lowered the intensity of subarachnoidal bleeding with significantly less intraventricular‐
haemorrhage.
The additional extension could be the evidence that pentadecapeptide BPC 157 particularly
attenuated neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) damage,
including mortality (Sikiric et al., 1999)(of note, neuroprotection by immunophillin ligands
lack the effect on MPTP-toxicity (Gold, 2000), significantly affected the dopamine system
(Jelovac et al., 1998, 1999; Sikiric et al., 1999)(a system also implicated in the traumatic brain
injury course) (Yan et al., 2001)and prevented/reversed catalepsy or stereotypy due to central
dopamine system failure induced by various procedures (Jelovac et al., 1998, 1999; Sikiric et
al., 1999). Accordingly, regional serotonin synthesis in the rat brain, assessed by α-methyl-L-
tryptophan autoradiographic measurements showed that, BPC 157 given peripherally may
readily cross the blood–brain barrier, affect region-specific brain 5-HT synthesis in rats leading
to significantly increased synthesis in the substantianigra (compacta and reticulata) structure
and counteract serotonin syndrome (BobanBlagaic et al., 2005; Tohyama et al., 2004). Very
recently, BPC 157 counteracts cuprizone-brain damage and motoric disability (Klicek et al.,
2013). An additional emphasize may be that BPC 157 largely interferes with different NSAIDs-




toxicity, including their brain damages that appear subsequently their gastrointestinal and/or
liver toxicity (Ilic et al., 2010, 2011, 2011).
Also, in addition to several other effects of BPC 157 (such as counteraction of acute and chronic
gastric lesions, blood pressure modulation and prevention/reversal of chronic heart failure
(Balenovic et al. 2009, 2012; Barisic et al., 2013)), BPC 157's antagonization of acute and chronic
ethanol intoxication (Blagaic AB et al., 2004) was found to be an effect that is at least partly
NO-dependent (Boban-Blagaic et al., 2006; Klicek et al., 2008; Lovric-Bencic et al., 2004; Sikiric
et al., 1997).
One possible option of treatment (i. e., injury is often irreversible because inability of nerve
tissue to regenerate and no therapeutic solution of this problem to date) is protection of
secondary injury – zone of vascular and inflammatory reaction in nerve tissue to primary
injury.
Taken together, the data providing the protection and rescue of the capsaicin neurotoxicity,
and thereby, the evidence for complex synergistic interaction between the beneficial effective‐
ness of BPC 157 and peptidergic sensory afferent neuron activity (Sikiric et al., 1996) was
useful,in a broader sense, for the further experiments. We argue that the significance of these
beneficial effects (Sikiric et al., 1996) was confirmed by the healing effect of pentadecapeptide
BPC 157 on transected and anastomosed as well as non-anastomosed rat sciatic nerve (Gjurasin
et al., 2010). The final prove was provided from brain trauma studies resulting in brain damage
and dysfunction from primary injury and subsequent secondary damage due to activation of
pathophysiologic cascades, but the preserved consciousness and reduced mortality in
pentadecapeptide BPC 157 treated along with lowered brain edema, lessened number and size
of haemorrhagic traumatic lacerations, subarachnoidal bleeding and intraventricularhaemor‐
rhage (Tudor et al., 2010).




BPC 157 10ng +/-
BPC 157 10µg +/-
Capsaicin +++ +++++
BPC 157 10ng + Capsaicin ++ +++
BPC 157 10µg + Capsaicin + +
Table 1. Long-term somatosensory neuron damage. Gastric lesions in 3-month-old adult rats following 48 hours
restraint stress, treated with capsaicin two weeks (125 mg/kg subcutaneously) before or as neonates at 7 days old (50
mg/kg subcutaneously). BPC 157 (10 ng or 10 µg per kg intraperitoneally) treatment 1 hour before restraint; 16-20
rats per each experimental group.
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BPC 157 10ng +/-
BPC 157 10µg +/-
Capsaicin 50mg +++++
BPC 157 10ng + Capsaicin 50mg ++
BPC 157 10µg + Capsaicin 50mg +
Table 2. Long-term somatosensory neuron damage. Gastric lesions in 3-month-old adult rats following subcutaneous
application of 30 mg/kg of indomethacin, treated with capsaicin as neonates at 7 days old (50 mg/kg
subcutaneously). BPC 157 (10 ng or 10 µg per kg intraperitoneally) treatment 1 hour before indomethacin
application; 16-20 rats per each experimental group.




BPC 157 10ng +
BPC 157 10µg +
Capsaicin +++ +++
BPC 157 10ng + Capsaicin + +++
BPC 157 10µg + Capsaicin + ++
Table 3. Long-term somatosensory neuron damage. Gastric lesions in 3-month-old adult rats 1 hour following
intragastric application of 96% ethanol, treated with capsaicin two weeks (125 mg/kg subcutaneously) before or as
neonates at 7 days old (50 mg/kg subcutaneously). BPC 157 (10 ng or 10 µg per kg intraperitoneally) treatment 1
hour before ethanol; 16-20 rats per each experimental group.
Excitation of somatosensory neurons in adult rats
Healthy +++++
BPC 157 10ng ++
BPC 157 10µg ++
Capsaicin 500µg ++++
BPC 157 10ng + Capsaicin 500µg +
BPC 157 10µg + Capsaicin 500µg +
Table 4. Excitation of somatosensory neurons. Gastric lesions in adult rats 1 hour following intragastric application of
96% ethanol, treated with capsaicin (low dose 500µg/kg, intraperitoneally) and/or BPC 157 (10 ng or 10 µg per kg
intraperitoneally) 1 hour before ethanol; 16-20 rats per each experimental group.
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